Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Influence of thrombolytic agents on human platelet function.

G H Rao1, R F Wilson, C W White

  • 1Laboratory Medicine and Pathology, University of Minnesota, Minneapolis 55455.

Thrombosis Research
|May 15, 1991
PubMed
Summary

Thrombolytic agents do not harm platelet function at therapeutic doses. While effective on whole blood clots, they do not dissolve platelet-rich plasma clots, highlighting platelets' role in reperfusion and reocclusion.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Size reduction-induced chain breaking in Haldane-chain compounds SrNi<sub>2-x</sub> Mg <sub>x</sub> V<sub>2</sub>O<sub>8</sub> (x  =  0 and 0.1).

Journal of physics. Condensed matter : an Institute of Physics journal·2017
Same author

Avoidance of Profound Hypothermia During Initial Reperfusion Improves the Functional Recovery of Hearts Donated After Circulatory Death.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2016
Same author

Physiologic Changes in the Heart Following Cessation of Mechanical Ventilation in a Porcine Model of Donation After Circulatory Death: Implications for Cardiac Transplantation.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2015
Same author

Disappearance of Ising nature in Ca3ZnMnO6 studied by high-field ESR.

Journal of physics. Condensed matter : an Institute of Physics journal·2014
Same author

Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

British journal of pharmacology·2011
Same author

Physiologic assessment of coronary artery stenosis severity.

Trends in cardiovascular medicine·2011

Area of Science:

  • Pharmacology
  • Hematology
  • Biochemistry

Background:

  • Thrombolytic agents are crucial for dissolving blood clots.
  • Understanding their interaction with platelets is vital for effective treatment.
  • Previous research has yielded conflicting results on thrombolytic effects on platelet function.

Purpose of the Study:

  • To evaluate the effects of four thrombolytic agents on platelet-rich plasma clots and platelet aggregation.
  • To determine if therapeutic concentrations of thrombolytic drugs adversely affect platelet function.
  • To investigate the role of platelets in clot lysis and thrombolytic therapy outcomes.

Main Methods:

  • Assessed clot retraction and platelet aggregation induced by various agonists.
  • Tested Streptokinase, Urokinase, and tissue plasminogen activator (t-PA) at different concentrations.

Related Experiment Videos

  • Incubated plasma and platelet-rich plasma with thrombolytic agents before clot formation.

    • Main Results:

    • Tissue plasminogen activator (t-PA) inhibited thrombin-induced clot formation and aggregation at high concentrations.
    • Streptokinase (Kabivitrum) potentiated weak agonist-induced platelet aggregation; Hoechst Streptokinase had no effect.
    • No tested thrombolytic agent adversely affected platelet function at therapeutic levels.
    • Thrombolytic agents lysed whole blood clots but not platelet-rich plasma clots.
    • Pre-incubation with thrombolytic agents prevented subsequent clot formation.

    Conclusions:

    • Thrombolytic drugs at therapeutic concentrations do not negatively impact platelet function.
    • Platelet-rich plasma clots are resistant to lysis by these agents, unlike whole blood clots.
    • Platelets may significantly influence reperfusion and reocclusion rates during in vivo thrombolytic therapy.